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Abstract 
Osteopetroses are a heterogeneous group of rare genetic bone diseases sharing the common 
hallmarks of reduced osteoclast activity, increased bone mass and high bone fragility.  Osteoclasts 
are bone resorbing cells that contribute to bone growth and renewal through the erosion of the 
mineralized matrix. Alongside the bone forming activity by osteoblasts, osteoclasts allow the 
skeleton to grow harmonically and maintain a healthy balance between bone resorption and 
formation. Osteoclast impairment in osteopetroses prevents bone renewal and deteriorates bone 
quality, causing atraumatic fractures. Osteopetroses vary in severity and are caused by mutations 
in a variety of genes involved in bone resorption or in osteoclastogenesis. Frequent signs and 
symptoms include osteosclerosis, deformity, dwarfism and narrowing of the bony canals, including 
the nerve foramina, leading to hematological and neural failures. The disease is autosomal, with 
only one extremely rare form associated so far to the X-chromosome, and can have either 
recessive or dominant inheritance. Recessive ostepetroses are generally lethal in infancy or 
childhood, with a few milder forms clinically denominated intermediate osteopetroses. Dominant 
osteopetrosis is so far associated only with mutations in the CLCN7 gene and, although described 
as a benign form, it can be severely debilitating, although not at the same level as recessive forms, 
and can rarely result in reduced life expectancy. Severe osteopetroses due to osteoclast 
autonomous defects can be treated by Hematopoietic Stem Cell Transplant (HSCT), but those due 
to deficiency of the pro-osteoclastogenic cytokine, RANKL, are not suitable for this procedure. 
Likewise, it is unclear as to whether HSCT, which has high intrinsic risks, results in clinical 
improvement in autosomal dominant osteopetrosis. Therefore, there is an unmet medical need to 
identify new therapies and studies are currently in progress to test gene and cell therapies, small 
interfering RNA approach and novel pharmacologic treatments. 
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Abbreviations 
ADO, Autosomal dominant osteopetroses; ATP6V1B1, V-type proton ATPase subunit B, kidney 
isoform; CAII, carbonic anhydrase type II; Cas9, CRISPR associated protein 9; CLCN7, Chloride 
channel 7; CRISPR, clustered regularly interspaced short palindromic repeats; CTX, Carboxy-
terminal collagen crosslinks; HEK293, Human embryonic kidney cells 293; HLA, Human leukocyte 
antigen; HSCT, Hematopoietic stem cell transplantation; IFN-γ, Interferon-γ; IKBKG, inhibitor of 
nuclear factor kappa-B kinase subunit gamma; IKK, IκB kinase; iPSCs, Induced pluripotent stem 
cells; LRP5, Low-density lipoprotein receptor-related protein 5; NEMO, NF-kappa-B essential 
modulator; OSTM1, Osteopetrosis-associated transmembrane protein 1; PLEKHM1, Pleckstrin 
homology domain-containing family M member 1; PTH, parathyroid hormone; RANK, Receptor 
Activator of NF-κB transcription factor; RANKL, Receptor Activator of NF-κB transcription factor 
Ligand; siRNA, small interfering RNA; SNX10, sorting nexin family; TCIRG1, V-type proton ATPase 
116 kDa subunit a isoform 3; TNFRSF11A, Tumor Necrosis Factor Receptor Superfamily, Member 
11a, NFKB Activator; TNFSF11, Tumor Necrosis Factor Superfamily Member 11; TRAcP, tartrate-
resistant acid phosphatase.
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Introduction 
Osteoclasts are the bone resorbing cells that, with their mineralized matrix erosion activity, 
contribute to the harmonic skeletal growth and continuous renewal of the tissue (1). The result of 
this intense activity is a balanced bone modeling and remodeling keeping bone healthy and 
mechanically competent (2). 
The hallmark of all osteopetroses is reduced osteoclast activity (3, 4). This impairment results in 
excessive bone mass, with a paradoxical decrease in bone strength. Osteopetroses are best 
classified based on their inheritance pattern. Recessive disease, which can be due to biallelic 
mutations in several genes, is generally very severe (5). Mutations in the gene coding for carbonic 
anhydrase tend instead to result in a more moderate phenotype, but with cognitive disabilities, as 
well as other morbidities (6). The dominant form of osteopetrosis, due to dominant negative 
mutations in the CLCN7 gene, can result in mild, moderate, but also severe disease, although with 
less infirmities than autosomal recessive forms (7-12).  
In this article, we describe the various forms of osteopetrosis and emphasize current and future 
approaches to therapy. 
1. Classification and clinical findings
2.1 Recessive osteopetroses 
The recessive forms of osteopetrosis have a combined prevalence of 1:250,000 live births and are 
due to mutations in several genes and a molecular diagnosis is obtainable for most patients (3-5). 
They are generally lethal within the first few years of life, with some survivors who may achieve 
childhood or early adolescence (3-5). These forms are characterized by brittle bones, which 
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radiologically appear diffusely dense, with long bone funnel-like extremities and alternating 
radiolucent lines, and extremely narrowed medullary cavities with bone-in-bone appearance (3-5) 
typical of growth arrest, consisting in denser marginal areas of mineralization, intermediate less 
dense areas and innermost denser areas (13). These features are pathognomonic and allow an 
accurate radiological diagnosis compared to other high bone mass conditions (14). 
The reduced size of the medullary cavities constrains the bone marrow leading to hematological 
failure (3-5). In fact, the early signs of recessive osteopetroses are anemia, leucopenia and 
susceptibility to infections (3-5). Infants also suffer from dwarfism, frontal bossing, deformities, 
osteomyelitis, hydrocephalous, and neurological symptoms (3-5,15). Blindness/visual loss is 
frequently present at diagnosis and, in the majority of patients, they are due to nerve compression 
caused by the narrowing of the poorly resorbed nerve foramina (3-5). Cognitive function is 
frequently normal except in recessive syndromes due to OSTM1 and, less frequently, to CLCN7 
gene mutations which cause primary neurodegeneration due to lysosomal storage disease 
affecting various areas of the brain, including cerebral and cerebellar cortices, hippocampus and 
retina (16,17). Furthermore, in other forms (gene implicated TCIRG1), patients also display 
increase of gastric pH, which may limit calcium absorption and contribute to hypocalcemia (19-
20). Based on data in mice (21), a similar increase of gastric pH could be hypothesized in patients 
harboring SNX10 mutations. 
There is a very high fracture rate in recessive patients due to poor quality of the non-remodeled 
bone (3-5,7). Moreover, these fractures show defective healing. Additionally, there is a high 
incidence of osteomyelitis most likely due to a combination of increased susceptibility to 
infections and poor blood flow to bone. In some patients (genes implicated TNFRSF11A), the poor 
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response to infections could be aggravated by a partial defect in the B-cell compartment (22), with 
a severity that increases with age and the progression of the disease. The TNFRSF11A and TNFSF11 
forms are also characterized by the inability to generate osteoclasts (22,23) and are classified as 
osteoclast-poor osteopetroses, as opposed to the other forms in which the numbers of 
nonfunctional osteoclasts are normal or even higher than normal, and are classified as osteoclast-
rich osteopetroses (24). 
The analysis of serum biomarkers of bone turnover has revealed that recessive patients are 
hypocalcemic, present with elevated alkaline phosphatase (osteoblast biomarker), reduced bone 
resorption biomarkers and increased brain creatin-kinase, a biomarker of uncertain meaning but 
rather consistently deregulated in osteopetroses (25,26). Since most forms of osteopetrosis are 
osteoclast-rich, tartrate-resistant acid phosphatase (TRAcP), an osteoclast biomarker, is increased, 
in line with the increased numbers of osteoclasts. In contrast, in osteoclast-poor osteopetrosis  the 
serum level of TRAcP is significantly lower than the normal values (25). Bone marrow aspirates in 
all forms of recessive osteopetrosis reveal severely reduced cellularity, while bone biopsies show 
persistence of primary trabeculae characterized by a core of calcified cartilage, typical of non-
remodeled bone (3-5). 
Mutations in the gene coding for carbonic anhydrase type II (CAII) cause an autosomal recessive 
osteopetrosis with variable severity (6). It is sometimes referred to as “intermediate 
osteopetrosis”. The exact prevalence is unknown, but it is rare. It presents not only with 
osteopetrosis, but also with renal tubular acidosis, cognitive impairment and cerebral calcifications 
(27). Paradoxically, in some subjects skeletal symptoms improve with age, although short stature, 
deformities, cognitive impairment and visual and hearing impairment persist. This might occur 
1 
2 
3 
4 
5 
6 
7 
8 
9 10 11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
7 
because low pH stimulates osteoclast activity, therefore, acidosis could mitigate their impairment 
(28). 
2.2 Dominant osteopetroses 
Autosomal dominant osteopetroses (ADO) are still referred to as type 1 and type 2. Type 1 is 
typically very mild but it appears now to be misclassified, being due to mutations of the LRP5 
gene, which affect osteoblasts (29,30). Therefore, it should be considered a “high bone mass” 
syndrome rather than an osteopetrosis. ADO2 (also known as “Albers-Schönberg disease” and 
“marble bone disease”) has a prevalence of approximately 1:20,000 live births (7) and a 
penetrance of approximately 66% (31). Because of the incomplete penetrance and a mild or 
asymptomatic phenotype in some individuals with CLCN7 gene mutations, ADO2 is sometimes 
referred to as the "benign" form of the disease to distinguish it from the "malignant" recessive 
form, which is generally  lethal in infancy (3-5,7). However, this “benign” designation is a 
misnomer and most ADO2 patients suffer complications from their disease. In our previous study, 
hip or femur fractures occurred in 16% of ADO2 children and 49% of ADO2 adults and our 4 most 
severely affected patients have died (25,31, Econs, unpublished observations). In our population, 
there was a high rate of severe visual loss due to lack of bone resorption to widen the optic canal 
during growth, with an overall prevalence of 19%. Additionally, 16% of our patients had 
osteonecrosis or osteomyelitis and bone marrow failure occurred in 3% of patients (31). Similar to 
our study, Benichou et al (32) studied 42 ADO2 patients and found that 78% of them had fractures 
and over half had orthopedic procedures with half of those having at least 3 procedures. They also 
had a high rate of mandibular osteomyelitis (12.9%). In contrast to our study (31), only 5% of 
patients had visual loss due to optic nerve compression (32). Thus, despite the high variability in 
the phenotype, ADO2 patients manifest significant, and in some cases, severe disease. 
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Radiologically, patients frequently show osteosclerosis of the skull base, pelvis and vertebras 
(3,7,31,32). These latter give rise to the so-called rugger-jersey spine because of the prominent 
multiple contiguous subendplate densities (sandwich vertebras), radiologically causing an 
alternating dense-lucent-dense appearance (3,7,31,32). Blood levels of TRAcP and the brain 
isoform of creatin-kinase are elevated (25,33,34). Low red cell and white cell counts occur in the 
most severely affected patients due to bone marrow failure (25,31,32). Thus, ADO2 displays 
incomplete penetrance and variable expressivity with some patients being quite severely affected. 
2. Cellular overview
Osteopetroses are osteoclast diseases, and they have been extremely important to understand 
various aspects of osteoclast biology, including the hematological and circulating origin of their 
precursors (35,36) as well as the molecular mechanisms of bone resorption (37). The 
understanding of these cellular features has been greatly facilitated by the availability of rodent 
models of osteopetroses, spontaneously occurring in mice and rats (37-39), and more recently 
obtained in mice by genetic manipulations (40,41). As stated above, based on the abundance of 
osteoclasts, osteopetroses are classified in two groups: osteoclast-rich, in which osteoclast 
numbers are normal or, more often, high, and osteoclast-poor, showing no osteoclasts (24). This 
classification highlights the ability of the individuals affected by the former to generate osteoclasts 
through the canonical osteoclastogenic pathways, and the inability of do so of those affected by 
the latter (24). 
3.1 Osteoclast-rich osteopetroses 
Osteoclast-rich osteopetroses represent the most frequent conditions, both in rodents and 
humans (24). They are seen in patients affected by recessive and dominant osteopetroses and, as 
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already stated, are characterized by normal or high serum levels of TRAcP, despite reduced 
biomarkers of bone resorption. Bone biopsies show normal or, most frequently, high number and 
surface of osteoclasts/bone surface, with low erosion surface/bone perimeter (25). Osteoclasts 
are easily recognized in bone biopsies through the histochemical detection of TRAcP (42). They 
line the bone surface but do not excavate Howship lacunas, a clear sign of impaired bone 
resorption. In several cases, the number of nuclei/osteoclast is high, suggesting that there is no 
impairment of fusions of precursors. At the transmission electron microscope, these osteoclasts 
may present imperfect polarization and lack of the ruffled border (43). 
In early studies, the high osteoclast number was thought to be an intrinsic feature of the disease. 
Later, the role of parathyroid hormone (PTH) in osteoclastogenesis was discovered (44) and 
clarified the origin of this cellular feature. PTH release is stimulated by low serum calcium 
concentration (45). Along with an intense osteoblast anabolic role (46), this hormone shows the 
peculiar ability to induce the production by osteoblasts of the most potent osteoclastogenic 
cytokine, Receptor Activator of NF-κB transcription factor Ligand (RANKL 
RANKL) (47). Favored by a concomitant reduction of the RANKL decoy receptor, osteoprotegerin 
(47), the excess of free RANKL stimulates osteoclast formation, with the unmet aim in 
osteopetrotic patients to return the calcemia to normal level. It is clear though that the 
osteoclastogenic process in osteoclast-rich osteopetroses is not disturbed, and that the molecular 
failure is within the mechanism of bone resorption (24). However, in ADO2 osteoclast number is 
high despite normal PTH concentrations, and in these patients it has been suggested that 
osteoclasts exhibit a prolonged lifespan caused by a yet to be determined pathway stimulating 
survival (48,49). 
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Of note, in bone biopsies of patients with osteoclast-rich autosomal recessive osteopetroses the 
small bone marrow still present in the narrow medullary cavities is strongly fibrotic with scant 
hematopoietic tissue left (25,42,50). 
3.2 Osteoclast-poor osteopetroses 
Much rarer in humans are the cases of osteoclast-poor osteopetroses. They represent a small 
percentage of the totality of cases of autosomal recessive osteopetroses and are characterized by 
low serum levels of TRAcP and no TRAcP-positive osteoclasts in bone biopsies (25). In these 
patients, the process of osteoclastogenesis is impeded by the lack of the osteoclastogenic cytokine 
RANKL (22), or of its receptor RANK (23). The former is a defect of the osteoblasts and other 
RANKL producing cells, including osteocytes and lymphocytes. The latter is an osteoclast-
autonomous defect due to lack of response to RANKL by the osteoclast precursors. Interestingly, 
at variance with the osteoclast-rich forms, in osteoclast-poor osteopetroses the small bone 
marrow tissue still present in the bone is not fibrotic, with some hematopoiesis still active (50), 
which could explain why patients survive longer. 
3. Genotype-phenotype correlation
The various clinical forms of osteopetrosis have recognized genetic traits (Table 1), with only less 
than 25% of patients harboring yet to be discovered gene mutations (5). 
4.1 Recessive osteopetroses 
About 50% of patients with autosomal recessive osteopetroses harbor mutations of the TCIRG1 
gene, which codes for the a3 subunit of the V-H+ATPase localized in the osteoclast ruffled border 
and in the gastric gland parietal cell apical membrane, where it releases protons to acidify the 
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extracellular environment (19,51). In osteoclasts, this environment, called Howship or resorption 
lacuna, is localized underneath the cell, between the ruffled border and the bone matrix, sealed at 
the periphery by the sealing membrane through its podosomal actin ring (1). Since the 
hydroxyapatite is strongly soluble in an acidic environment, this low pH demineralizes the bone, 
exposing the organic matrix to the lysosomal enzymes therein released, especially cathepsin K, 
which cleaves type I collagen in small fragments (52). In the gastric gland parietal cells, protons are 
released into the lumen where the gastric juice denatures and digests the protein content of the 
food. Gastric acidification is also essential for calcium uptake through the gastro-intestinal tract, 
the consequence of which in this form of the disease is, as already stated, a rickets- or 
osteomalacia-like phenotype that adds to the osteopetrotic phenotype (19,20). 
Osteopetrotickets or osteopetromalacia are not observed in bone biopsies of forms of autosomal 
recessive osteopetroses due to loss-of-function mutations of the CLCN7 and the OSTM1 genes. 
Patients harboring CLCN7 or OSTM1 gene mutations display an overlapping phenotype (16,17), 
with some differences compared to those affected by TCIRG1 or SNX10 gene mutations. This 
observation suggests that the two proteins are implicated in the same molecular cascade (53). In 
fact, the CLCN7 gene codes for the ClC-7 protein, which is a 2-chloride/1-proton antiporter 
localized in the acidic vesicle and ruffled border membranes. CIC-7 charge balances the positive 
protons that are discharged by the V-H+ATPase and releases chloride ions essential for acidifying 
the osteoclast lacunae space (16). OSTM1 encodes for the Ostm1 protein, which is classified as the 
ClC-7 β-subunit, essential for the correct trafficking and subcellular localization of the ClC-7 (53). 
As mentioned above, the peculiar phenotype of these forms of osteopetrosis is a severe primary 
neurodegeneration observed in brain and retina (16,17). This phenotype is due to a lysosomal 
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storage disease and is most reproducible in OSTM1-patients, while the situation is more 
heterogeneous in CLCN7-patients (18). 
The SNX10 gene mutations affect about 4% of patients with recessive osteopetroses (5,54) and is 
characterized by few and small osteoclasts (54). The protein coded by this gene interacts with the 
V-H+ATPase and is probably involved in the sorting of this complex to the ruffled border (54). 
Osteoclasts from mouse models of SNX10 deficiency show defective endocytosis, extracellular 
acidification and ruffled border formation, which leads to impaired bone resorption (54). The 
protein is also expressed in the stomach, where high pH and low calcium solubilization are 
observed (22). Consequently, the SNX10 global knock-out mouse bone phenotype is consistent 
with osteopetrorickets, as opposed to the osteoclast-specific knock-out mice that show 
ostepetrosis but not rickets (21). 
Two genes whose mutations are known to cause severe osteopetroses code for the 
osteoclastogenic cytokine RANKL (TNFSF11) expressed by the osteoblasts, and its receptor RANK 
(TNFRSF11A) expressed by the osteoclast precursors, accounting for 5% of patients each (55). The 
RANKL/RANK pathway is implicated in the process of osteoclast formation, therefore these forms 
of osteopetrosis are osteoclast-poor (24), and in bone biopsies the TRAcP histochemical staining 
detects no positive cells (25). Paradoxically, these patients survive a bit more than those affected 
by the other forms described above, although they are severely compromised and some of those 
affected by TNFRSF11A mutations suffer also from hypogammaglobilinemia (22). 
The only X-chromosome-linked osteopetrosis occurs in the so-called OL-EDA-ID syndrome 
characterized by lymphedema, anhidrotic ectodermal dysplasia and immunodeficiency. Patients 
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show a moderate osteopetrosis with no neurosensory impairments (56). The gene implicated is 
called IKBKG and codes for NEMO, the regulatory subunit of the IKK complex, essential to activate 
the NF-κB transcription factor and induce osteoclastogenesis. OL-EDA-ID is lethal in early infancy 
and there are no studies on its prevalence in the osteopetrotic population. However, according to 
the paucity of data in literature, it is likely to be a very rare disease in which osteopetrosis is not 
the most severe condition. Since NEMO belongs to the osteoclastogenic signaling cascade (57), it 
is thought that OL-EDA-ID displays an osteoclast-poor osteopetrosis. However, no data are 
available in literature therefore the cellular alterations occurring in the bones of these patients 
remain to be elucidated. Furthermore, this form is currently untreatable due to the severity of 
manifestations besides osteopetrosis. 
An autosomal recessive loss-of-function mutation of the PLEKHM1 gene has been found to induce 
a moderately severe form of osteopetrosis (39). Plekhm1 is a protein involved in vesicular 
trafficking, the mutation of which prevents the formation of the osteoclast ruffled border and 
impairs the resorption of bone (39). Plekhm1 is associated with small GTPases, and is co-localized 
with Rab7 in late endosomes and lysosomes, which are major contributors of membrane transport 
to the ruffled border (39,58). 
Autosomal recessive loss-of-function mutations of the CAII gene, coding for carbonic anhydrase 
type 2, are responsible for what was sometimes referred to as “intermediate osteopetrosis” (6). 
This cytosolic enzyme catalyzes the hydration of CO2 into H2CO3, supplying the V-H
+ATPase with
protons derived by the H2CO3 dissociation (40). The resulting HCO
-
3 is exchanged with chloride by
an anion exchanger located in the osteoclast basolateral membrane (59,60), which in turn fuels 
the ruffled border ClC-7 antiporter. The CAII gene is highly expressed also in the kidney tubular 
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cells (61), therefore these patients present with renal tubular acidosis, which is a specific hallmark 
of this form of osteopetrosis (40). The reason why this form has a milder course than other forms 
of recessive osteopetroses is believed to depend on a low rate of spontaneous CO2 hydration 
occurring into the cells, therefore, even in the absence of a functional carbonic anhydrase, the 
acidification of the lacuna is not totally prevented. Furthermore, an improvement of the bone 
phenotype may be seen with time, probably due to the beneficial effect of acidosis on osteoclast 
function (28). In contrast, patients suffer from cerebral calcifications of unknown origin, which 
challenge the neural function inducing cognitive impairment (40). 
Finally, a peculiar and very rare form of severe osteopetrosis can be confused with CAII deficiency. 
Borthwick et al. (62) identified in a patient penetrant mutations in two different genes. One 
mutation was a homozygous deletion in the TCIRG1 gene, which was associated with a 
homozygous mutation in the ATP6V1B1 gene coding for the B1 subunit of the V-H+ATPase 
specifically expressed in the kidney. The result of this complex genetic trait was a severe 
osteopetrosis, with renal tubular acidosis that phenocopied the CAII deficiency. 
4.2 Autosomal Dominant Osteopetroses 
The only gene implicated so far in dominant forms of osteopetrosis is the CLCN7, in which various 
types of mutations cause ADO2 by a dominant negative mechanism (8-12, 63-68).  As noted 
above, ADO1, which is caused by mutations in the LRP5 gene, should be reclassified as affected by 
high bone mass syndrome (29). 
The CLCN7 gene codes for the ClC-7 subunit of the 2Cl-/1H+ antiporter localized in the acidic 
vesicles and ruffled border compartment of the osteoclast (53). This subunit dimerizes and 
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associates with the Ostm1 protein, which is essential for its correct localization (53). Through its 
stoichiometry of 2 chlorides against 1 proton, the antiporter releases negative charges into the 
acidic vesicles and the Howship lacuna, which balance the transport of positive charges by the V-
H*ATPase (1). Since the CLCN7 gene is haplosufficient, its biallelic loss-of-function mutations can 
only cause the autosomal recessive osteopetrosis described above as a severe form of the 
diseases, while heterozygous subjects are healthy carriers (16). In contrast, in ADO2, the gene 
harbors mostly missense mutations with dominant negative feature, in which the mutant subunits 
can still dimerize although they have impaired function (53). Consequently, an assortment of 
normal homodimers and mutated homo- and heterodimers are believed to be expressed by 
patients. 
Interestingly, the mutant CLCN7 gene has an incomplete penetrance, accounting for about 66% of 
patients presenting with symptoms (31). The remaining patients are healthy, can be considered 
normal carriers and are generally recognized through the genetic screening of the affected 
families (31). Many families have both non-penetrant carriers and severely affected individuals. 
The molecular mechanisms of the incomplete penetrance remain to be elucidated. The gene is 
made up by 25 exons and is highly polymorphic (69), but it is unclear whether specific 
polymorphisms could be associated with its incomplete penetrance (69-71). Environmental 
modifiers, genetic modifiers as well as epigenetic regulation could represent other mechanisms 
favoring the incomplete penetrance, but further work is necessary to discover those specifically 
modulating the expression of the dominant negative CLCN7 gene mutants. Understanding these 
features could help identify new and specific molecular targets for therapy. 
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The affected patients display a wide variety of symptoms, ranging from solely radiographic 
features to repeated atraumatic fractures, as well as compromised vision and hearing and 
occasional bone marrow failure (31,32). Furthermore, since the CLCN7 gene is widely expressed in 
the body, it is unlikely that the bone is the only affected tissue. Since the loss-of-function 
mutations of the CLCN7 gene in the autosomal recessive osteopetrosis may also induce 
neurodegeneration, attention should be paid to central neural disorders. Generally, they are not 
reported in patients with ADO2, although rare cases of cognitive failure are known (25). However, 
a recent mouse model carrying the ClC-7G213R mutant in heterozygous status shows increased 
anxiety and depression correlated with accumulation of β-amyloid bodies in neurons (72). 
Whether anxiety and depression is a primary consequence of the genetic defect in humans as well 
or if these conditions result from being chronically ill is unknown. Furthermore, the CLCN7 gene 
exhibits significant expression in various organs and in our ADO2 mouse model we observed a mild 
multiorgan perivascular fibrosis that is several-fold aggravated in the homozygous status (Teti, 
unpublished information), which could contribute to the early death of the mice within the first 
month of life (73). Further studies should be performed in patients to determine if they also 
display a phenotype in other organs.  
4. Therapy of osteopetroses
5.1 Current therapies 
As noted, mouse models of osteopetroses have been instrumental to identify the hematologic 
and circulating origin of the osteoclast precursors (35,36). These observations indicated that 
HSCT would be a useful therapy for many forms of autosomal recessive osteopetroses (74).  
Although there have been many improvements in HSCT over the years, it remains a dangerous 
procedure with many toxicities (18). Therefore, it is reserved for patients with severe disease. 
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These patients typically have recessive disease and there is no data to determine whether HSCT 
works in severe cases of ADO2, although the bone disease in these patients can also be very 
debilitating. 
There are two contraindications to this therapeutic procedure: the diagnosis of the osteoclast 
non-autonomous form due to mutation of RANKL, and of the OSTM1 and, less frequently, the 
CLCN7 genes mutations. 
In RANKL deficiency, the hematopoietic stem cells cannot replace the stromal/osteoblast cells that 
produce the mutant RANKL (23,75). These cells belong to the skeletal stem cell lineage and 
support skeletal regeneration, hematopoiesis and osteoclastogenesis (76). Their transplant could 
in theory supply the healthy cytokine, but their use in medicine is still limited (77), although 
progress is being made for instance for the treatment of pediatric diseases, including the 
osteogenesis imperfecta (78-80). Furthermore, the engraftment of mesenchymal stem cells has 
been met with unexpected difficulties, which again limit their current use for therapies in humans 
(76,77). However, intense investigation is being performed, especially showing mesenchymal stem 
cell homing to sites of inflammation or tissue damage, where they seem to adsorb 
immunosuppressive drugs enhancing their immunomodulator properties (81) as well as their 
potential for the treatment of graft versus host disease (82). 
Osteopetroses due to biallelic mutations in the OSTM1 and the CLCN7 genes in theory can be 
treated with HSCT. However, the serious neurodegeneration observed in brain and retina, 
especially in OSTM1 deficient patients, cannot be cured by this procedure, therefore cognitive 
function and vision remain severely compromised (18). However, while the OSTM1 form 
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constantly presents with severe neuropathy, patients with CLCN7 gene mutations may be free of 
neurodegeneration (18). Therefore, it is current practice to carefully evaluate CLCN7 patients 
neurologically and consider HSCT if there are no or limited signs of neurological impairment (18).  
Although HSCT is a risky procedure, in recent years many outstanding centers made significant 
improvements, saving lives of an increasing number of patients (83). However, HSCT still presents 
some pitfalls. Engraftment problems may consist in delay of hematological recovery, active 
rejection especially in patients transplanted with HLA-haploidentical stem cells above 10 months 
of age, stable mixed chimerism and extinction of donor cells, which may require a second 
transplant (18). Further complications may be represented by graft versus host disease, liver or 
pulmonary veno-occlusive disease, respiratory problems with upper airway obstruction, secondary 
ventilation problems due to fluid overload, infections and primary pulmonary hypertension (18). 
Hypercalcemia is also observed, especially after HLA-identical transplant, which can require 
treatment with anti-resorptive drugs, including bisphosphonates or denosumab (18). 
Although the treatment regimen with HSCT is effective in restoring normal bone resorption and 
hematopoiesis, there are still some drawbacks that affect the children. In a systematic 
retrospective study performed between 1980 and 2001, it appeared clear that the 5 years disease 
free survival was dramatically affected by the HLA genotype of the donors. While HLA-identical 
recipients had a chance of survival greater than 70%, this chance dropped to about 40% for 
recipients of HLA-mismatch transplant from a related donor or matched unrelated donor, down to 
24% for children receiving a graft from a HLA-haplotype-mismatch related donor (15). However, 
improvement is constantly observed in more recent years for all transplant groups, especially in 
the case of HLA-haploidentical transplant, whose rate of success has been assessed around 60% 
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from 1993 to 2007 (18). Death after transplant is most frequently due to graft failure and early-
transplant complications, which makes this treatment regimen unfeasible for intermediate and 
milder forms of osteopetroses. 
Death is not the only severe post-transplant negative outcome. Visual impairment is often not 
cured because of optical nerve atrophy that cannot be restored (15). However, it has been 
observed that visual preservation or improvement is more frequent in children transplanted below 
3 months of age (15), highlighting the importance of rapid diagnosis and therapy. Likewise, 
dwarfism, cognitive impairment (if present), and primary neuropathy in OSTM1 and in CLCN7 (if 
present) loss-of-function gene mutations, are not cured by HSCT. Nevertheless, when successful, 
HSCT can lead to a relatively good quality of life (18). 
When HSCT is not possible, alternative therapies are employed. However, they cannot replace 
HSCT as they are not curative interventions. Interferon-γ (IFN-γ) is approved for use in severe 
recessive osteopetroses, but currently it is not included in the common clinical practice. In fact, it 
is only used as a bridge therapy to allow patients to survive until an acceptable donor for HSCT is 
found and, to the best of our knowledge, there are no recent reports updating on the clinical 
outcome.  In a study published in 1995, Key et al. (84) treated 14 patients with recessive 
osteopetroses with IFN-γ.  After 6 months of therapy, all patients demonstrated decreases in 
trabecular bone area and increases in marrow space. Mean hemoglobin concentration increased 
(from 7.5 ±2.9 g/dL to 10.5 ±0.3 g/dL), demonstrating improvement in bone marrow function. 
Superoxide generation increased and there was a marked reduction in infections. Improvements 
were sustained in the 11 patients who were treated for 18 months. Thus, IFN-γ is a useful therapy 
while waiting for a suitable donor for HSCT. 
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Currently, there are no accepted therapies for dominant osteopetrosis and, unfortunately, for 
many patients with either recessive or dominant osteopetroses the major thrust of therapy is 
supportive. This includes blood transfusions for bone marrow failure and frequent orthopedic 
procedures to attempt to stabilize fractures.  Of note, orthopedic procedures are frequently 
difficult and the risk of infection is high (85). Additional supportive therapies include analgesics to 
reduce pain and antibiotics to treat osteomyelitis. Previous therapies with PTH, vitamin D3 and 
calcium supplementation (86-89) have resoundingly failed. Furthermore, patients affected by 
RANKL deficiency cannot benefit from HSCT therefore this form of severe osteopetrosis is 
currently incurable. Thus, there is a critical need to better understand the pathogenesis of these 
disorders to find new and effective interventions. 
5.2 Future therapies 
As noted above, it is clear that scientists must continue to investigate the natural history of the 
disease to find alternative strategies. Fortunately, a number of studies are already in progress and 
could lead in reasonable time to therapeutic innovations. 
Being a hematologic disease, future approaches could be based on gene therapy, at least for the 
severe forms. This approach could liberate patients from the need to search HLA-matched donors, 
as it would allow the correction of the genetic disease in autologous hematopoietic stem cells (90). 
Recent success of classical gene therapy by lentivirus transduction used to cure congenital 
immunodeficiencies (90) is very promising. Equally promising are the new approaches of genome 
editing, especially through the CRISPR/Cas9 technology (91). Likewise, recent studies have 
emphasized the theoretical possibility to use corrected autologous induced pluripotent stem cells 
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(iPSCs) (92). iPSCs injected in immunodeficient mice gives rise to teratomas, showing their in vivo 
multilineage differentiation capacity. To prevent this important complication, in a hypothetic 
therapeutic approach, iPSCs should be differentiated in vitro into the required cell lineage and 
differentiated cells should then be selected prior to their use in vivo. iPSCs are indeed the object of 
intense interest in human medicine already holding promise for instance for the therapy of retinal 
diseases (93). 
RANKL deficiency will require a different approach. Pharmacologic treatment with recombinant 
soluble RANKL is in theory a good alternative. In the tnfsf11 knockout mice it has been observed 
the rescue of the bone phenotype and beneficial effects on the bone marrow, spleen and thymus 
with a systematic administration of RANKL for 1 month. The study faced the severe adverse 
accumulation of the cytokine with consequent lethal overdose, likely inducing an expansion of 
lymphoid aggregates already present in the lungs of untreated mice and subsequent respiratory 
failure (94). However, these adverse effects could be prevented by dose titration and skeletal 
monitoring followed by dose tapering when the skeletal phenotype is rescued. 
In the context of this form of osteopetrosis, two further lines of research are currently being 
pursued: skeletal (mesenchymal) stem cell transplant and biotechnological implants. 
Skeletal stem cells are mesenchymal in origin. They replenish the osteoblast component of bone 
and support hematopoiesis (76). Therefore, they are theoretically ideal to be allo- or auto-
transplanted to generate an osteoblast population capable of producing RANKL, even upon gene 
manipulation or genome editing procedures. Unfortunately, there are no applications yet of 
mesenchymal stem cells in medicine (77) and more studies are necessary to fully understand their 
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biology prior of considering them a suitable tool to combat RANKL deficiency. Furthermore, 
infusion of mesenchymal stem cells for a systemic disease, that in this specific case is not 
hematological in origin, is still challenging and there are no studies supporting the feasibility of this 
procedure. 
As an alternative, RANKL-producing skeletal stem or progenitor cells could be implanted 
subcutaneously, in specific biotechnological devices, which could then have a systemic effect by 
releasing soluble RANKL. This has been done in mouse models using calvarial osteoblasts 
inoculated in diffusion chambers along with a hydroxyapatite support functionalized by adsorption 
of the catalytic domain of metalloproteinase-14, an ectoenzyme that cleaves membrane bound 
RANKL into soluble and active RANKL (95). This biotechnological manipulation was shown to 
induce the release of enough soluble RANKL to trigger osteoclastogenesis in a RANKL-deficient 
mouse model, thus demonstrating promise for future development. The method could have 
several advantages, including physiologic regulation of RANKL and osteoprotegerin expression, 
lack of immune response against the donor cells, which are separated by the host immune system 
through the porous membrane of the diffusion chambers, and the possibility of inoculating the 
diffusion chambers with engineered cells which could express soluble RANKL in a controlled 
manner, theoretically preventing adverse overdose effects. 
ADO2 could instead be a good candidate for RNA interfering procedures. One approach is RNA 
silencing, which has been successfully used in our laboratory in the heterozygous Clcn7G213R mouse 
model of ADO2, based on the concept that the CLCN7 gene is haplosufficient and mutant-specific 
small interfering RNA (siRNA) are able to silence only the mutant gene, leaving the normal gene 
intact (96) (Figure 1A). We have designed siRNAs for three frequent mutations, CLCN7G215R-, 
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CLCN7R767W- and CLCN7R286W which proved effective in silencing the respective mutant mRNA in 
transfected HEK293 cells, RAW264.7 cells and human osteoclasts. None of these siRNAs changed 
the expression of the normal CLCN7 mRNA and no effect was observed using control scrambled 
siRNA. The CLCN7G215R-specific siRNA, rescued normal bone resorption in osteoclasts harvested 
from a patient, as well as in osteoclasts obtained from the Clcn7G213R mice, carrying the mouse 
homologue of the human mutant gene. Most importantly, this experimental therapy was effective 
and specific also in vivo (96). Treatment of Clcn7G213R mice with CLCN7G215R-specific siRNA, which 
also complement the mouse mutant gene, improved the bone structural (Figure 1B) and cellular 
variables rescuing a normal bone phenotype in 4 weeks (96). We were able to obtain in vivo proof 
of concept of effective treatment also with siRNAs specific for the other mutants (96). 
Hypothetical adverse events of siRNA therapy could include non-specific off-target effects and 
induction of pro-inflammatory response.  With our siRNA strategy targeted exclusively to the 
mutant gene, we did not observe any of these events nor did we note other overt adverse effects 
(96). These results demonstrate that a siRNA-based experimental treatment of ADO2 is feasible, 
and underscore a future translational impact for this strategy. 
Using a similar ADO2 mouse model (same mutation, different strain) we tested whether IFN-γ or 
high dose calcitriol could increase bone resorption and decrease bone mass.  Six-week-old male 
and female ADO2 mice were treated with vehicle, calcitriol, or IFN-γ at three different doses for 8 
weeks. Mice treated with low and medium doses of calcitriol showed a trend toward higher bone 
mineral density and bone volume over total tissue volume, whereas high dose calcitriol 
significantly increased bone mass compared to vehicle (97). In contrast, all doses of IFN-γ 
significantly attenuated the increase of whole body bone mineral density (97) and bone volume 
over total tissue volume at the distal femur in both male and female ADO2 mice as compared to 
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those treated with vehicle (Figure 2A). Importantly, the reduction in bone volume due to IFN-γ 
treatment was to a level approximately half way between wildtype mice and ADO2 mutant mice, 
indicating that there was an incomplete, but meaningful reduction in the abnormal bone 
phenotype. Additionally, the serum Carboxy-terminal collagen crosslinks (CTX) and the CTX/TRAcP 
ratio were increased in the IFN-γ groups, but not in the calcitriol treated groups (Figure 2B), 
indicating that there was an increase in bone resorption with IFN-γ treatment (97). This study 
demonstrates that IFN-γ has potential to at least partially treat human ADO2 and a clinical trial in 
patients is currently underway (98).  
5. Conclusions
The natural history of osteopetroses is a journey in the biology of osteoclasts and, through this 
group of diseases scientists gained an understanding of the molecular mechanisms underlying 
osteoclastogenesis and bone resorption. These pioneering studies have laid the foundation for 
current osteoclast biology and technological investigations and, importantly, for the 
comprehension of the pathogenesis of other diseases involving osteoclasts. Not only the field of 
osteopetrosis, but also the fields of osteoporosis and other pathological conditions in which the 
osteoclasts are secondarily affected (i.e. osteogenesis imperfecta, osteoporosis pseudoglioma 
syndrome, fibrous dysplasia, rheumatoid arthritis, juvenile idiopathic arthritis, etc.) have largely 
benefited from these developments, as these patients receive now anti-resorptive treatments to 
strengthen the bone. Unfortunately, there are still important limitations in the treatment of 
osteopetroses, since effective therapies are not available for all forms, can be dangerous, and do 
not fully rescue the phenotype. However, we look forward to forthcoming developments, which 
are expected to bring substantial innovation in the field, providing patients and their families with 
a hope for their future. 
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Table 1: Forms of osteopetroses, genes implicated and phenotype. 
Form Gene Osteoclast 
phenotype 
Clinical 
Phenotype 
Autosomal 
Recessive 
TCIRG1 
CLCN-7 
OSTM1 
TNFRSF11A 
TNFSF11 
SNX10 
Rich 
Rich 
Rich 
Poor 
Poor 
Rich (?) 
Severe, osteopetrorickets 
Severe, possible neurodegeneration 
Severe, neurodegeneration 
Severe 
Severe, osteoblast-intrinsic defect 
Severe, osteopetrorickets 
Intermediate 
Recessive 
PLEKHMI 
CA II 
Rich 
Rich 
Intermediate 
Intermediate, renal tubular acidosis, cerebral 
calcifications 
Autosomal 
Dominant 
CLCN-7 Rich From mild to severe, rarely lethal 
X-linked NEMO Poor (?) Severe, immunodeficiency, ectodermal dysplasia 
(?) No sufficient data available 
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Figure legends 
Figure 1 – Treatment of ADO2 mice with mutant-specific siRNA. (A) Rational for the use of siRNA 
therapy in ADO2. ClC-7 protein is a homodimer. In healthy individuals, both subunits are normal 
(NN), while in ADO2 one or both subunits are mutated (M), giving rise to nonfunctional or 
malfunctional heterodimers (NM) or homodimers (MM). The CLCN7 gene is haplosufficient, 
therefore removal of the mutant subunits through highly specific siRNA that does not affect the 
expression of the normal subunits is expected to return the phenotype near to a physiologic 
condition. (B) Ten-day old Clcn7G213R/WT ADO2 mice were treated for 2 weeks with 4mg/Kg 
Clcn7G213R-specific siRNA or scrambled siRNA as control. Micro-computed tomography of the 
proximal tibias reveals a lower trabecular volume over total bone volume (BV/TV) in Clcn7G213R-
specific siRNA-treated mice. N=6-8. Mean+standard deviation; p=0.04, Student’s t test. 
Figure 2 – Interferon-γ significantly attenuated the BV/TV gain and increased the serum 
CTX/TRAP ratio in ADO2 mice.  ADO2 mice treated with all doses of INF-γ displayed (A) reduced 
bone volume/total volume (BV/TV) and (B) increased Carboxy-terminal collagen crosslinks over 
Tartrate Resistant Acid Phosphatase (CTXTRAcP) ratio, indicating increased resorption per 
osteoclast.  L = low dose; M = medium dose; H = high dose (80). V = vehicle. 
1 
2 
3 
4 
5 
6 
7 
8 
9 10 11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
42 
Figure 1 
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